The Australian Living Evidence Collaboration (ALEC) last week published a guideline providing interim advice on drug treatments for people with influenza who are critically ill. Development of the guideline was triggered by a recent preliminary trial result that suggested oseltamivir, the current first-line treatment for influenza in people who are critically ill, is not effective and may be harmful in...

On June 10, the REMAP-CAP trial released a preliminary result that suggests that oseltamivir (Tamiflu) is not effective, and may be harmful, in adult patients with influenza in...

The Australian Living Evidence Collaboration is aware of the preliminary results recently released from the REMAP-CAP trial, with implications for the treatment of patients with influenza in critical...